1. Introduction to Paracetamol & Diclofenac Sodium Tablets IP (BMR):
Paracetamol & Diclofenac Sodium Tablets IP are combination pharmaceutical formulations containing two active pharmaceutical ingredients: Paracetamol IP 325 mg and Diclofenac Sodium IP 50 mg per uncoated tablet. Paracetamol provides analgesic and antipyretic effects, while Diclofenac Sodium is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and inflammation. This combination is intended for managing painful inflammatory conditions under medical supervision. The Batch Manufacturing Record (BMR) provides comprehensive documentation of manufacturing activities, ensuring product quality, consistency, traceability, and compliance with Good Manufacturing Practices (GMP). The manufacturing process described in the BMR includes raw material dispensing, sifting, binder preparation, wet granulation, drying, milling, blending, lubrication, tablet compression, and subsequent quality control activities. Critical manufacturing parameters such as mixing time, drying temperature, granule moisture content, tablet weight, hardness, friability, and disintegration are monitored according to approved specifications. The BMR also incorporates equipment identification, line clearance, in-process quality checks, material reconciliation, batch yield calculations, and production verification records. Proper implementation of the BMR supports systematic manufacturing control, accurate documentation, effective quality assurance, and consistent production of Paracetamol & Diclofenac Sodium Tablets IP in accordance with established pharmaceutical manufacturing standards.
Skip to PDF content2. Manufacturing Process Flow Diagram for Paracetamol & Diclofenac Sodium Tablets IP (BMR):
The manufacturing process flow diagram for Paracetamol & Diclofenac Sodium Tablets IP illustrates the systematic sequence of operations involved in producing uncoated tablets containing Paracetamol IP 325 mg and Diclofenac Sodium IP 50 mg. The process follows Good Manufacturing Practices (GMP) to ensure product quality, consistency, and traceability. Manufacturing begins with raw material dispensing, where active pharmaceutical ingredients and excipients are accurately weighed according to the approved Batch Manufacturing Record (BMR). The materials undergo sifting to remove lumps and ensure uniform particle distribution.
Binder preparation involves preparing starch paste, followed by wet granulation using a Rapid Mixer Granulator (RMG). The wet granules are processed through a multimill and dried in a Fluid Bed Dryer (FBD) under specified conditions. The dried granules undergo sizing, blending, and lubrication to achieve suitable flow and compression characteristics. Subsequently, the lubricated granules are compressed into tablets using a compression machine. In-process quality control includes monitoring tablet weight, hardness, thickness, friability, and disintegration. Following satisfactory quality checks, tablets proceed to blister packing, finished product testing, secondary packaging, and labeling. Finally, the finished goods are transferred to designated storage areas under controlled conditions, with release subject to Quality Assurance approval.
3. Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Paracetamol & Diclofenac Sodium Tablets IP:
The Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Paracetamol & Diclofenac Sodium Tablets IP play an essential role in ensuring consistent product quality, safety, and manufacturing performance. Each uncoated tablet contains Paracetamol IP 325 mg and Diclofenac Sodium IP 50 mg.
Critical Process Parameters (CPP)
Critical Process Parameters are manufacturing variables whose variability can affect product quality and therefore require appropriate monitoring and control. Important process parameters include raw material dispensing accuracy, sieve integrity, binder preparation, granulation time, mixing speed, drying temperature, granule moisture content, blending time, lubrication time, and compression settings. During wet granulation, binder addition and mixing conditions influence granule formation. Fluid Bed Dryer temperature and drying duration are controlled to achieve the specified granule moisture content. Blending and lubrication conditions influence powder uniformity and compression performance. Compression force, turret speed, and tablet weight settings are monitored to maintain consistent tablet characteristics.
Critical Quality Attributes (CQA)
Critical Quality Attributes are the physical, chemical, biological, or microbiological properties that must remain within established limits to ensure acceptable product quality. Important quality attributes include tablet appearance, average weight, weight variation, thickness, hardness, friability, disintegration, assay, dissolution, related substances, and packaging integrity. These attributes are evaluated through appropriate in-process checks and finished product testing according to approved specifications and applicable Indian Pharmacopoeia requirements.
Conclusion
Effective monitoring of CPPs and verification of CQAs support a controlled manufacturing process, minimize batch variability, and ensure consistent product quality. All parameters and acceptance criteria must be established through approved manufacturing documents, process validation, and quality risk assessments in accordance with Good Manufacturing Practices (GMP).